Association of tartrate-resistant acid phosphatase-expressed macrophages and metastatic breast cancer progression

Yu Guang Chen, Anthony Janckila, Tsu Yi Chao, Ren Hua Yeh, Hong Wei Gao, Su Huei Lee, Jyh Cherng Yu, Guo Shiou Liao, Ming Shen Dai

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Infiltrating neutrophils, lymphocytes, macrophages, and cytokines constitute a state of chronic inflammation within the tumor microenvironment. Tartrate-resistant acid phosphatase 5a (TRACP5a) protein, a novel product of activated macrophage, is postulated to be a biomarker for systemic inflammatory burden in states of chronic inflammation. We aimed to investigate the clinical significance of TRACP5a expression in tumor-infiltrating macrophages and serum TRACP5a in patients with metastatic breast cancer (BC). We retrospectively analyzed the clinical data from 34 BC patients with confirmed skeletal/visceral metastasis upon or during first-line palliative treatment. Patients were stratified into 3 groups based on the therapeutic responses and follow-up disease course. The association ofTRACP5a protein with other inflammatory and cancer biomarkers was assessed among the clinically distinct group of patients. Higher TRACP5a protein was significantly correlated with earlier disease progression and survival (P=0.0045) in comparison to other inflammatory markers, CRP or IL-6. Patients with higher serum TRACP5a level and shorter survival and treatment refractoriness also had more TRACP+ tumor-infiltrating macrophages. Our data support a hypothesis that serum TRACP5a protein can potentially be a predictive and prognostic marker to evaluate disease progression and therapeutic response in BC patients with bone/visceral metastasis. The associations between overall survival and TRACP expression by macrophages require further prospective investigation.

Original languageEnglish
Article numbere2165
JournalMedicine (United States)
Volume94
Issue number48
DOIs
Publication statusPublished - 2015

Fingerprint

Macrophages
Breast Neoplasms
Survival
Disease Progression
Proteins
Serum
Neoplasm Metastasis
Inflammation
Tumor Microenvironment
Tumor Biomarkers
Palliative Care
Tartrate-Resistant Acid Phosphatase
Interleukin-6
Neoplasms
Neutrophils
Therapeutics
Biomarkers
Lymphocytes
Cytokines
Bone and Bones

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Association of tartrate-resistant acid phosphatase-expressed macrophages and metastatic breast cancer progression. / Chen, Yu Guang; Janckila, Anthony; Chao, Tsu Yi; Yeh, Ren Hua; Gao, Hong Wei; Lee, Su Huei; Yu, Jyh Cherng; Liao, Guo Shiou; Dai, Ming Shen.

In: Medicine (United States), Vol. 94, No. 48, e2165, 2015.

Research output: Contribution to journalArticle

Chen, Yu Guang ; Janckila, Anthony ; Chao, Tsu Yi ; Yeh, Ren Hua ; Gao, Hong Wei ; Lee, Su Huei ; Yu, Jyh Cherng ; Liao, Guo Shiou ; Dai, Ming Shen. / Association of tartrate-resistant acid phosphatase-expressed macrophages and metastatic breast cancer progression. In: Medicine (United States). 2015 ; Vol. 94, No. 48.
@article{e72af57a4a54476dac27e7d7d9e99112,
title = "Association of tartrate-resistant acid phosphatase-expressed macrophages and metastatic breast cancer progression",
abstract = "Infiltrating neutrophils, lymphocytes, macrophages, and cytokines constitute a state of chronic inflammation within the tumor microenvironment. Tartrate-resistant acid phosphatase 5a (TRACP5a) protein, a novel product of activated macrophage, is postulated to be a biomarker for systemic inflammatory burden in states of chronic inflammation. We aimed to investigate the clinical significance of TRACP5a expression in tumor-infiltrating macrophages and serum TRACP5a in patients with metastatic breast cancer (BC). We retrospectively analyzed the clinical data from 34 BC patients with confirmed skeletal/visceral metastasis upon or during first-line palliative treatment. Patients were stratified into 3 groups based on the therapeutic responses and follow-up disease course. The association ofTRACP5a protein with other inflammatory and cancer biomarkers was assessed among the clinically distinct group of patients. Higher TRACP5a protein was significantly correlated with earlier disease progression and survival (P=0.0045) in comparison to other inflammatory markers, CRP or IL-6. Patients with higher serum TRACP5a level and shorter survival and treatment refractoriness also had more TRACP+ tumor-infiltrating macrophages. Our data support a hypothesis that serum TRACP5a protein can potentially be a predictive and prognostic marker to evaluate disease progression and therapeutic response in BC patients with bone/visceral metastasis. The associations between overall survival and TRACP expression by macrophages require further prospective investigation.",
author = "Chen, {Yu Guang} and Anthony Janckila and Chao, {Tsu Yi} and Yeh, {Ren Hua} and Gao, {Hong Wei} and Lee, {Su Huei} and Yu, {Jyh Cherng} and Liao, {Guo Shiou} and Dai, {Ming Shen}",
year = "2015",
doi = "10.1097/MD.0000000000002165",
language = "English",
volume = "94",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "48",

}

TY - JOUR

T1 - Association of tartrate-resistant acid phosphatase-expressed macrophages and metastatic breast cancer progression

AU - Chen, Yu Guang

AU - Janckila, Anthony

AU - Chao, Tsu Yi

AU - Yeh, Ren Hua

AU - Gao, Hong Wei

AU - Lee, Su Huei

AU - Yu, Jyh Cherng

AU - Liao, Guo Shiou

AU - Dai, Ming Shen

PY - 2015

Y1 - 2015

N2 - Infiltrating neutrophils, lymphocytes, macrophages, and cytokines constitute a state of chronic inflammation within the tumor microenvironment. Tartrate-resistant acid phosphatase 5a (TRACP5a) protein, a novel product of activated macrophage, is postulated to be a biomarker for systemic inflammatory burden in states of chronic inflammation. We aimed to investigate the clinical significance of TRACP5a expression in tumor-infiltrating macrophages and serum TRACP5a in patients with metastatic breast cancer (BC). We retrospectively analyzed the clinical data from 34 BC patients with confirmed skeletal/visceral metastasis upon or during first-line palliative treatment. Patients were stratified into 3 groups based on the therapeutic responses and follow-up disease course. The association ofTRACP5a protein with other inflammatory and cancer biomarkers was assessed among the clinically distinct group of patients. Higher TRACP5a protein was significantly correlated with earlier disease progression and survival (P=0.0045) in comparison to other inflammatory markers, CRP or IL-6. Patients with higher serum TRACP5a level and shorter survival and treatment refractoriness also had more TRACP+ tumor-infiltrating macrophages. Our data support a hypothesis that serum TRACP5a protein can potentially be a predictive and prognostic marker to evaluate disease progression and therapeutic response in BC patients with bone/visceral metastasis. The associations between overall survival and TRACP expression by macrophages require further prospective investigation.

AB - Infiltrating neutrophils, lymphocytes, macrophages, and cytokines constitute a state of chronic inflammation within the tumor microenvironment. Tartrate-resistant acid phosphatase 5a (TRACP5a) protein, a novel product of activated macrophage, is postulated to be a biomarker for systemic inflammatory burden in states of chronic inflammation. We aimed to investigate the clinical significance of TRACP5a expression in tumor-infiltrating macrophages and serum TRACP5a in patients with metastatic breast cancer (BC). We retrospectively analyzed the clinical data from 34 BC patients with confirmed skeletal/visceral metastasis upon or during first-line palliative treatment. Patients were stratified into 3 groups based on the therapeutic responses and follow-up disease course. The association ofTRACP5a protein with other inflammatory and cancer biomarkers was assessed among the clinically distinct group of patients. Higher TRACP5a protein was significantly correlated with earlier disease progression and survival (P=0.0045) in comparison to other inflammatory markers, CRP or IL-6. Patients with higher serum TRACP5a level and shorter survival and treatment refractoriness also had more TRACP+ tumor-infiltrating macrophages. Our data support a hypothesis that serum TRACP5a protein can potentially be a predictive and prognostic marker to evaluate disease progression and therapeutic response in BC patients with bone/visceral metastasis. The associations between overall survival and TRACP expression by macrophages require further prospective investigation.

UR - http://www.scopus.com/inward/record.url?scp=84952320684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952320684&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000002165

DO - 10.1097/MD.0000000000002165

M3 - Article

C2 - 26632898

AN - SCOPUS:84952320684

VL - 94

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 48

M1 - e2165

ER -